Bio Nano Consulting targets US biotechnology market
4 Oct 2010
Bio Nano Consulting (BNC), a joint venture of Imperial College
London and University College London, has commenced a US tour meeting
biotechnology and pharmaceutical leaders. BNC is aiming to promote
nanotechnology partnerships with US biotechnology companies.
Dr David Sarphie, BNC’s CEO commented: “BNC has successfully
delivered a number of contracts in the US where UK innovation and
knowledge has helped solve some real-world problems for US clients.
We see significant opportunities for US expansion due to the
increasing pressures to reduce costs, increase speed to market and
decrease attrition rates.
“The US visit to San Francisco and Boston aims to highlight to a
wider life science audience how nanotechnology can help improve
product development. This includes increasing the knowledge of how
drugs really interact with their targets, by solving formulation
problems to increase bioavailability, and to promoting BNC’s unique
services in accessing academic research and expertise combined with
a strong commercial imperative. We believe that BNC’s services
provide a win-win scenario by solving client problems and also
ensuring academic expertise has commercial relevance.”
Planned activities include:
Tuesday 5 October, San Francisco.
8:30 – 10:30. Breakfast Event
‘Nanotechnology in Drug Discovery’
11:30 – 13:30. Radio
Interviews with Dr Moira Gunn on BioTech Nation on NPR.
Thursday 7 October, Boston, MA.
16:00 – 19:30. Event:
‘Nanotechnology in Drug Discovery and Development’, British
Consulate General, 1 Main St, Cambridge MA.
20:30. Speakers & special guest dinner. Top of the Hub,
Prudential Centre, Boston. Proposed Guests: Dr Bruce Pratt, Genzyme;
Dan Passerie, CEO Curis Inc; Pepper Denman, GE Healthcare; Dr
Gunther Winkler, Biogen Idec.